Rakez Kayed

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/582343/publications.pdf

Version: 2024-02-01

171 papers	28,418 citations	17440 63 h-index	10158 140 g-index
200 all docs	200 docs citations	200 times ranked	24984 citing authors

#	Article	IF	Citations
1	Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. Science, 2003, 300, 486-489.	12.6	3,748
2	Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles. Neuron, 2003, 39, 409-421.	8.1	3,609
3	A specific amyloid-Î² protein assembly in the brain impairs memory. Nature, 2006, 440, 352-357.	27.8	2,662
4	Curcumin Inhibits Formation of Amyloid Î² Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo. Journal of Biological Chemistry, 2005, 280, 5892-5901.	3.4	2,024
5	Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*â™¦. Journal of Biological Chemistry, 2005, 280, 17294-17300.	3.4	886
6	Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases. Journal of Biological Chemistry, 2004, 279, 46363-46366.	3.4	798
7	NLRP3 inflammasome activation drives tau pathology. Nature, 2019, 575, 669-673.	27.8	782
8	iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron, 2017, 94, 278-293.e9.	8.1	730
9	Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular Neurodegeneration, 2007, 2, 18.	10.8	655
10	Small Molecule Inhibitors of Aggregation Indicate That Amyloid Î² Oligomerization and Fibrillization Pathways Are Independent and Distinct. Journal of Biological Chemistry, 2007, 282, 10311-10324.	3.4	620
11	The Role of Amyloid-Î² Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine, 2016, 6, 42-49.	6.1	534
12	Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Molecular Neurodegeneration, 2011, 6, 39.	10.8	462
13	Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons. Journal of Biological Chemistry, 2013, 288, 1856-1870.	3.4	436
14	Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB Journal, 2012, 26, 1946-1959.	0.5	420
15	Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. Chemical Reviews, 2021, 121, 2545-2647.	47.7	406
16	Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Scientific Reports, 2012, 2, 700.	3.3	396
17	Structural and Dynamic Features of Alzheimer's AÎ² Peptide in Amyloid Fibrils Studied by Site-directed Spin Labeling. Journal of Biological Chemistry, 2002, 277, 40810-40815.	3.4	361
18	Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in Vitro. Journal of Molecular Biology, 1999, 287, 781-796.	4.2	340

#	Article	IF	Citations
19	Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology, 2006, 66, S74-S78.	1.1	322
20	Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer. Journal of Biological Chemistry, 2009, 284, 4230-4237.	3.4	307
21	Preparation and Characterization of Neurotoxic Tau Oligomers. Biochemistry, 2010, 49, 10039-10041.	2.5	302
22	Molecular Mechanisms of Amyloid Oligomers Toxicity. Journal of Alzheimer's Disease, 2012, 33, S67-S78.	2.6	294
23	Desmin-related cardiomyopathy in transgenic mice: A cardiac amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10132-10136.	7.1	262
24	Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. Journal of Clinical Investigation, 2013, 123, 4158-4169.	8.2	246
25	Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles. Journal of Neuroscience, 2014, 34, 4260-4272.	3.6	241
26	Soluble Amyloid Oligomers Increase Bilayer Conductance by Altering Dielectric Structure. Journal of General Physiology, 2006, 128, 637-647.	1.9	211
27	Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. Journal of Clinical Investigation, 2006, 116, 378-385.	8.2	179
28	Loss of Î±7 Nicotinic Receptors Enhances Î²-Amyloid Oligomer Accumulation, Exacerbating Early-Stage Cognitive Decline and Septohippocampal Pathology in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2010, 30, 2442-2453.	3.6	171
29	Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers Are Intracellular, and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does Not Prevent h-IAPP-Induced Â-Cell Apoptosis in h-IAPP Transgenic Mice. Diabetes, 2007, 56, 1324-1332.	0.6	167
30	ERK1/2 Activation Mediates AÎ² Oligomer-induced Neurotoxicity via Caspase-3 Activation and Tau Cleavage in Rat Organotypic Hippocampal Slice Cultures. Journal of Biological Chemistry, 2006, 281, 20315-20325.	3.4	159
31	Conformationâ€Dependent Antiâ€Amyloid Oligomer Antibodies. Methods in Enzymology, 2006, 413, 326-344.	1.0	146
32	Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds. Journal of Alzheimer's Disease, 2014, 40, S97-S111.	2.6	145
33	Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. Biological Psychiatry, 2015, 78, 672-683.	1.3	140
34	Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2016, 55, 1083-1099.	2.6	138
35	Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar AÎ² oligomers. Molecular Neurodegeneration, 2010, 5, 57.	10.8	135
36	AÎ² Amyloid Pathology Affects the Hearts of PatientsÂWithÂAlzheimerâ€™s Disease. Journal of the American College of Cardiology, 2016, 68, 2395-2407.	2.8	132

#	Article	IF	Citations
37	Alzheimerâ€™s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain, 2021, 144, 288-309.	7.6	132
38	Amyloid-Î² Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain. Journal of Biological Chemistry, 2011, 286, 22122-22130.	3.4	127
39	Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2015, 35, 4857-4868.	3.6	122
40	Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury. Journal of Biological Chemistry, 2013, 288, 17042-17050.	3.4	115
41	Soluble AÎ² oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Research, 2005, 1031, 222-228.	2.2	109
42	Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiology of Aging, 2007, 28, 1689-1699.	3.1	107
43	Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13592-13597.	7.1	100
44	Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimerâ€™s disease from a ferroptosis perspective. Progress in Neurobiology, 2020, 184, 101716.	5.7	98
45	Formation and Propagation of Tau Oligomeric Seeds. Frontiers in Neurology, 2013, 4, 93.	2.4	95
46	Amyloid Formation by the Pro-Inflammatory S100A8/A9 Proteins in the Ageing Prostate. PLoS ONE, 2009, 4, e5562.	2.5	95
47	Isolation, Structural, and Functional Characterization of an Apoptosis-Inducing -Amino Acid Oxidase from Leaf-Nosed Viper (Eristocophis macmahoni) Snake Venom. Archives of Biochemistry and Biophysics, 2000, 384, 216-226.	3.0	94
48	Î±â€Synuclein oligomers oppose longâ€term potentiation and impair memory through a calcineurinâ€dependent mechanism: relevance to human synucleopathic diseases. Journal of Neurochemistry, 2012, 120, 440-452.	3.9	94
49	Amyloidâ€Î² oligomers impair fear conditioned memory in a calcineurinâ€dependent fashion in mice. Journal of Neuroscience Research, 2010, 88, 2923-2932.	2.9	93
50	Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochemical Pharmacology, 2014, 88, 468-478.	4.4	93
51	Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and crossâ€seeding behavior. Protein Science, 2018, 27, 1901-1909.	7.6	88
52	Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell, 2008, 7, 824-835.	6.7	87
53	TDP-43 Phosphorylation by casein kinase Iîµ promotes oligomerization and enhances toxicity in vivo. Human Molecular Genetics, 2014, 23, 1025-1035.	2.9	83
54	Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimerâ€™s Disease and Related Tauopathies. , 2017, 8, 257.		82

#	Article	IF	Citations
55	Pore-Forming Proteins Share Structural and Functional Homology with Amyloid Oligomers. NeuroMolecular Medicine, 2007, 9, 270-275.	3.4	78
56	P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2020, 8, 132.	5.2	78
57	Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimerâ€™s disease and frontotemporal dementia. Cell Reports, 2021, 36, 109419.	6.4	78
58	Amyloid Î², Tau, and Î±-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Progress in Neurobiology, 2022, 214, 102270.	5.7	77
59	Exercise reverses preamyloid oligomer and prolongs survival in ÂB-crystallin-based desmin-related cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5995-6000.	7.1	76
60	Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathologica Communications, 2014, 2, 73.	5.2	76
61	Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. Biochemical and Biophysical Research Communications, 2013, 430, 963-968.	2.1	75
62	Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. Journal of Neurotrauma, 2016, 33, 2034-2043.	3.4	75
63	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2017, 4, 226-235.	3.7	72
64	Advances and considerations in AD tau-targeted immunotherapy. Neurobiology of Disease, 2020, 134, 104707.	4.4	70
65	Amyloid-Î² Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines. Journal of Alzheimer's Disease, 2010, 20, 637-646.	2.6	69
66	Î±-Synuclein Oligomers Induce a Unique Toxic Tau Strain. Biological Psychiatry, 2018, 84, 499-508.	1.3	65
67	Potential mechanisms and implications for the formation of tau oligomeric strains. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 482-496.	5.2	64
68	Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species. ACS Chemical Neuroscience, 2014, 5, 752-769.	3.5	63
69	The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathologica Communications, 2014, 2, 56.	5.2	62
70	The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration. Aging Cell, 2015, 14, 715-724.	6.7	61
71	Tau oligomers mediate Î±-synuclein toxicity and can be targeted by immunotherapy. Molecular Neurodegeneration, 2018, 13, 13.	10.8	60
72	RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction. Nature Communications, 2020, 11, 4305.	12.8	60

#	Article	IF	Citations
73	Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo. Neurobiology of Disease, 2015, 82, 540-551.	4.4	59
74	Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin. Molecular Neurodegeneration, 2008, 3, 16.	10.8	57
75	Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimerâ€™s disease, progressive supranuclear palsy and dementia with Lewy bodies. Cell Death and Disease, 2020, 11, 314.	6.3	56
76	Amyloid-Î² oligomers as a template for secondary amyloidosis in Alzheimer's disease. Neurobiology of Disease, 2014, 71, 14-23.	4.4	55
77	Tau Interacts with the C-Terminal Region of Î±-Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations. Biochemistry, 2019, 58, 2814-2821.	2.5	55
78	TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. Neurobiology of Disease, 2020, 146, 105130.	4.4	55
79	Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model. Neurobiology of Disease, 2016, 87, 19-28.	4.4	54
80	Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Current Opinion in Immunology, 2009, 21, 359-363.	5.5	52
81	Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives. Scientific Reports, 2019, 9, 19011.	3.3	50
82	Differential Activation of the ER Stress Factor XBP1 by Oligomeric Assemblies. Neurochemical Research, 2012, 37, 1707-1717.	3.3	45
83	Selective lowering of synapsins induced by oligomeric Î±-synuclein exacerbates memory deficits. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4648-E4657.	7.1	45
84	Prospects for strain-specific immunotherapy in Alzheimerâ€™s disease and tauopathies. Npj Vaccines, 2018, 3, 9.	6.0	45
85	LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. Journal of Lipid Research, 2005, 46, 115-122.	4.2	41
86	A fibril-specific, conformation-dependent antibody recognizes a subset of AÎ² plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathologica, 2009, 118, 505-517.	7.7	41
87	Soluble endogenous oligomeric Î±-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk. Journal of Parkinson's Disease, 2020, 10, 1-28.	2.8	40
88	Neurotoxic tau oligomers after single versus repetitive mild traumatic brain injury. Brain Communications, 2019, 1, fcz004.	3.3	35
89	Modulating disease-relevant tau oligomeric strains by small molecules. Journal of Biological Chemistry, 2020, 295, 14807-14825.	3.4	35
90	Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. Molecular Neurodegeneration, 2012, 7, 37.	10.8	34

#	Article	IF	Citations
91	Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum Vaccin, 2010, 6, 931-935.	2.4	33
92	Critical Role of the CXCL10/C-X-C Chemokine Receptor 3 Axis in Promoting Leukocyte Recruitment and Neuronal Injury during Traumatic Optic Neuropathy Induced by Optic Nerve Crush. American Journal of Pathology, 2017, 187, 352-365.	3.8	33
93	Astrocytes contain amyloid-Î² annular protofibrils in Alzheimer's disease brains. FEBS Letters, 2011, 585, 3052-3057.	2.8	32
94	Tau Oligomers in Sera of Patients with Alzheimerâ€™s Disease and Aged Controls. Journal of Alzheimer's Disease, 2017, 58, 471-478.	2.6	32
95	Poloxamer 188 Copolymer Membrane Sealant Rescues Toxicity of Amyloid Oligomers In Vitro. Journal of Molecular Biology, 2009, 391, 577-585.	4.2	31
96	Tau aggregates as immunotherapeutic targets. Frontiers in Bioscience - Scholar, 2013, S5, 426-438.	2.1	31
97	Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. Methods in Molecular Biology, 2017, 1523, 141-157.	0.9	30
98	Azure C Targets and Modulates Toxic Tau Oligomers. ACS Chemical Neuroscience, 2018, 9, 1317-1326.	3.5	30
99	A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. ELife, 2015, 4, .	6.0	29
100	Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 113.	5.2	28
101	Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies. Molecular Neurobiology, 2019, 56, 3341-3355.	4.0	28
102	Tau oligomers mediate aggregation of RNAâ€binding proteins Musashi1 and Musashi2 inducing Lamin alteration. Aging Cell, 2019, 18, e13035.	6.7	28
103	Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimerâ€™s Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers. Journal of Alzheimer's Disease, 2020, 78, 1661-1678.	2.6	28
104	Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 89-102.	3.7	27
105	Rational design, conformational studies and bioactivity of highly potent conformationally constrained calcitonin analogues. FEBS Journal, 1999, 265, 606-618.	0.2	26
106	Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes. Frontiers in Molecular Neuroscience, 2021, 14, 742790.	2.9	26
107	Polymorphic Î±-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein. Molecular Neurobiology, 2020, 57, 2741-2765.	4.0	25
108	Association of Skin with the Pathogenesis and Treatment of Neurodegenerative Amyloidosis. Frontiers in Neurology, 2012, 3, 5.	2.4	23

#	Article	IF	Citations
109	Following Activation of the Amyloid Cascade, Apolipoprotein E4 Drives the in vivo Oligomerization of Amyloid-Î² Resulting in Neurodegeneration. Journal of Alzheimer's Disease, 2010, 22, 959-970.	2.6	22
110	CNI-1493 inhibits AÎ² production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. Journal of Experimental Medicine, 2008, 205, 1593-1599.	8.5	21
111	Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimerâ€™s disease. Journal of Biological Chemistry, 2022, 298, 101766.	3.4	20
112	The Influence of the Carboxyl Terminus of the Alzheimer AÎ² Peptide on its Conformation, Aggregation, and Neurotoxic Properties. NeuroMolecular Medicine, 2002, 1, 81-94.	3.4	19
113	Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides. Chemical Communications, 2018, 54, 10120-10123.	4.1	19
114	Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain. Brain Research, 2005, 1045, 224-228.	2.2	18
115	Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification. International Journal of Alzheimer's Disease, 2009, 2009, 1-7.	2.0	18
116	Antibody against Small Aggregated Peptide Specifically Recognizes Toxic AÎ²-42 Oligomers in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2015, 6, 1981-1989.	3.5	16
117	AAV2-mediated GRP78 Transfer Alleviates Retinal Neuronal Injury by Downregulating ER Stress and Tau Oligomer Formation. , 2018, 59, 4670.		16
118	Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers. Aging Cell, 2021, 20, e13455.	6.7	16
119	Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes. ELife, 2015, 4, .	6.0	16
120	Design of Metastable Î²-Sheet Oligomers from Natively Unstructured Peptide. ACS Chemical Neuroscience, 2013, 4, 1520-1523.	3.5	15
121	Therapeutic Approaches Targeting Pathological Tau Aggregates. Current Pharmaceutical Design, 2016, 22, 4028-4039.	1.9	15
122	AÎ²/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2022, 79, 222.	5.4	14
123	Preparation and Characterization of Tau Oligomer Strains. Methods in Molecular Biology, 2018, 1779, 113-146.	0.9	13
124	Tau induces formation of Î±-synuclein filaments with distinct molecular conformations. Biochemical and Biophysical Research Communications, 2021, 554, 145-150.	2.1	13
125	Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intraâ€lesional injections of antiâ€amyloid antibodies. Experimental Dermatology, 2010, 19, 904-911.	2.9	12
126	Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis. Journal of the American Academy of Dermatology, 2011, 65, 1023-1031.	1.2	11

#	Article	IF	Citations
127	Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?. ImmunoTargets and Therapy, 2014, 3, 19.	5.8	11
128	Early alterations of neurovascular unit in the retina in mouse models of tauopathy. Acta Neuropathologica Communications, 2021, 9, 51.	5.2	11
129	Post-translational Modifications of the p53 Protein and the Impact in Alzheimerâ€™s Disease: A Review of the Literature. Frontiers in Aging Neuroscience, 2022, 14, 835288.	3.4	11
130	Curcumin as Scaffold for Drug Discovery against Neurodegenerative Diseases. Biomedicines, 2021, 9, 173.	3.2	10
131	Dynamic interactions and Ca2+-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding. Nature Communications, 2021, 12, 6292.	12.8	10
132	Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins. Journal of Central Nervous System Disease, 2011, 3, JCNSD.S5018.	1.9	9
133	Oligomer Formation and Crossâ€Seeding: The New Frontier. Israel Journal of Chemistry, 2017, 57, 665-673.	2.3	8
134	Î²-Amyloid (AÎ²) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation. Molecular and Cellular Neurosciences, 2005, 28, 496-508.	2.2	7
135	Infectious etiology and amyloidosis in Alzheimer's disease: The puzzle continues. Journal of Biological Chemistry, 2021, 297, 100936.	3.4	7
136	The amyloid concentric Î²â€barrel hypothesis: Models of amyloid beta 42 oligomers and annular protofibrils. Proteins: Structure, Function and Bioinformatics, 2022, 90, 1190-1209.	2.6	5
137	New vaccine development for chronic brain disease. Neuropsychopharmacology, 2010, 35, 354-354.	5.4	4
138	Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 102-17.	1.0	3
139	Caspase inhibition mitigates tau cleavage and neurotoxicity in iPSCâ€induced neurons with the V337MÂ MAPTÂ mutation. Alzheimer's and Dementia, 2021, 17, e051471.	0.8	2
140	[P4â€“456]: TAU AND P53 IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1505.	0.8	1
141	P1â€025: EXOSOMES CONTAINING SPECIFIC TAU OLIGOMER FORMATIONS ACCELERATE PATHOLOGICAL TAU PHOSPHORYLATION IN C57BL/6 MICE. Alzheimer's and Dementia, 2018, 14, P275.	0.8	1
142	Amyloid oligomer interactions and polymorphisms: disease-relevant distinct assembly of Î±-synuclein and tau. Neuropsychopharmacology, 2019, 44, 222-223.	5.4	1
143	Elucidating the pathogenic mechanisms of AD brainâ€derived, tauâ€containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons. Alzheimer's and Dementia, 2020, 16, e037316.	0.8	1
144	Quantification and targeting of elusive neurotoxic amyloid oligomers. Cell Reports Medicine, 2022, 3, 100636.	6.5	1

#	Article	IF	Citations
145	Tau Oligomers as Potential Drug Target for Alzheimer Disease (AD) Treatment. , 2011, , .		0
146	O4â€06â€01: Specific clearance of tau oligomers by passive immunization. Alzheimer's and Dementia, 2012, 8, P624.	0.8	0
147	P1-122: OLIGOMERS OF A-SYNUCLEIN CROSS-SEED TAU AND EXTEND LIFETIME OF TAU TOXIC CONFORMATION. , 2014, 10, P345-P345.		0
148	P3-066: TDP-43 HYBRID OLIGOMERS IN ALZHEIMER'S DISEASE. , 2014, 10, P651-P651.		0
149	O1-08-06: TAU OLIGOMERS DERIVED FROM TRAUMATIC BRAIN INJURY CAUSE TOXICITY AND COGNITIVE IMPAIRMENT IN HTAU MICE. , 2014, 10, P146-P146.		0
150	P4-215: TAU OLIGOMER-SPECIFIC ANTIBODIES IN INTRAVENOUS IMMUNOGLOBULINS (IVIGS): POTENTIAL THERAPEUTIC SIGNIFICANCE IN ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE TAUOPATHIES. , 2014, 10, P866-P867.		0
151	P2-071: PATHOLOGICAL TAU SPECIES ABROGATE NASCENT PROTEIN PRODUCTION BY ASSOCIATING WITH THE RIBOSOMAL COMPLEX: IMPLICATIONS OF A NOVEL TAU FUNCTION AND ITS PATHOGENIC LINK TO MEMORY IMPAIRMENT. , 2014, 10, P495-P496.		0
152	O5-04-01: DIFFERENT OLIGOMERIC TAU STRAINS ARE DETECTED WITH NOVEL ANTI-TAU OLIGOMER-SPECIFIC ANTIBODIES. , 2014, 10, P297-P297.		0
153	[F4â€“07â€“03]: TAU OLIGOMERIC STRAINS IN SYNUCLEINOPATHIES. Alzheimer's and Dementia, 2017, 13, P1219.	0.8	0
154	[P4â€“406]: INVESTIGATING THE POTENTIAL OF NOVEL CURCUMIN DERIVATIVES IN TARGETING AND MODULATING TOXIC TAU OLIGOMERIC STRAINS. Alzheimer's and Dementia, 2017, 13, P1486.	0.8	0
155	[O1â€“07â€“03]: SYNAPTIC RESILIENCE TO TAU AND AMYLOID BETA OLIGOMERS INDUCED BY NEURAL STEM CELLâ€DERIVED EXOSOMES. Alzheimer's and Dementia, 2017, 13, P205.	0.8	0
156	[P4â€“451]: TBI AND AD: SIMILAR TAUâ€INDUCED NEURODEGENERATION?. Alzheimer's and Dementia, 2017, 13, P1503.	0.8	0
157	O2â€02â€06: PROPAGATION AND DIVERSE EFFECTS OF DISEASEâ€SPECIFIC PRIONâ€LIKE TAU OLIGOMERIC STRAINS. Alzheimer's and Dementia, 2018, 14, P612.	0.8	0
158	P1â€021: TOXICITY AND PROPAGATION OF TBI BRAINâ€DERIVED SOLUBLE TAU STRAINS. Alzheimer's and Dementia, 2018, 14, P273.	0.8	0
159	O2â€01â€03: SELECTED MICRO RNAS FROM NEURAL STEM CELLâ€“DERIVED EXOSOMES INCREASE SYNAPTIC RESILIENCE TO TAU AND AÎ² OLIGOMERS. Alzheimer's and Dementia, 2018, 14, P609.	0.8	0
160	P3â€170: INCREASED SYNAPTIC SENSITIVITY TO AÎ² AND TAU OLIGOMERS IN THE AGING CNS AS A FUNCTION OF DECREASING NEURAL STEM CELLS. Alzheimer's and Dementia, 2018, 14, P1133.	0.8	0
161	P3â€167: INHIBITION OF PHOSPHOLIPASE D1 AS A THERAPEUTIC IN ADâ€RELATED MEMORY DEFICITS. Alzheimer's and Dementia, 2018, 14, P1131.	0.8	0
162	P4â€023: TAU IMMUNOTHERAPY FOR ALPHAâ€SYNUCLEINOPATHY. Alzheimer's and Dementia, 2018, 14, P1442.	0.8	0

#	Article	IF	Citations
163	O5â€05â€06: EVALUATING TAU OLIGOMERS PASSIVE IMMUNOTHERAPY USING AGED TRANSGENIC ANIMALS OF TAUOPATHY. Alzheimer's and Dementia, 2018, 14, P1657.	0.8	0
164	O4â€05â€04: Tau Immunotherapy for Alphaâ€Synucleinopathy. Alzheimer's and Dementia, 2018, 14, P1412.	0.8	0
165	P4â€520: TAU OLIGOMERS MEDIATE AGGREGATION OF RNAâ€BINDING PROTEINS MUSASHI1â€•AND MUSASHI2â€INDUCING NUCLEAR MEMBRANE ALTERATION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1513.	0.8	0
166	Differential dynamics of AÎ² and tau oligomer synaptic binding may suggest diverse therapeutic targets for early vs. late Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e038045.	0.8	0
167	Innate immune activation of the NLRP3 inflammasome pathway drives tau pathology. Alzheimer's and Dementia, 2020, 16, e039815.	0.8	0
168	Tau Oligomer Induced HMGB1 Release Contributes to Cellular Senescence and Neuropathology Linked to Alzheimer's Disease and Frontotemporal Dementia. SSRN Electronic Journal, 0, , .	0.4	0
169	A Complex Containing HNRNPA2B1 and N ⁶-Methyladenosine Modified Transcripts Mediates Actions of Toxic Tau Oligomers. SSRN Electronic Journal, 0, , .	0.4	0
170	AD- and PSP-specific brain-derived tau oligomers engage synapses with different dynamic.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054394.	0.8	0
171	Tau modulates mRNA transcription, alternative polyadenylation (APA) profiles of hnRNPs, chromatin remodeling and spliceosome complexes. FASEB Journal, 2022, 36, .	0.5	0